Takashi Onoe

Takashi Onoe

Auto-generated profile, based on publicly available information

Takashi Onoe

Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; Institute for Clinical Research, National Hospital Organization, Kure Medical Center/Chugoku Cancer Center, Kure, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
HYHideyuki Yanai
Hideyuki Yanai
SCShiho Chiba
Shiho Chiba
TBTatsuma Ban
Tatsuma Ban
YNYukana Nakaima
Yukana Nakaima
TOTakashi Onoe
Takashi Onoe
TTTadatsugu Taniguchi
Tadatsugu Taniguchi
The activation of innate immune responses by nucleic acids is central to the generation of host responses against pathogens; however, nucleic acids can also trigger the development and/or exacerbation of pathogenic responses such as autoimmunity. We previously demonstrated that the selective activation of nucleic acid-sensing cytosolic and Toll-like receptors is contingent on the promiscuous sensing of nucleic acids by high-mobility group box proteins (HMGBs). From this, we reasoned that nonimmunogenic nucleotides with high-affinity HMGB binding may function as suppressing agents for HMGB-mediated diseases, particularly those initiated and/or exacerbated by nucleic acids. Here we characterize an array of HMGB-binding, nonimmunogenic oligodeoxynucleotides (ni-ODNs). Interestingly, we find that binding affinity is rather independent of nucleotide sequence, but is instead dependent on length and structure of the deoxyribose backbone. We further show that these ni-ODNs can strongly suppress the activation of innate immune responses induced by both classes of nucleic acid-sensing receptors. We also provide evidence for the suppressive effect of an ni-ODN, termed ISM ODN, on the induction of adaptive immune responses and in mouse models of sepsis and autoimmunity. We discuss our findings in relation to the critical role of HMGBs in initiating immune responses and the possible use of these ni-ODNs in therapeutic interventions.

1 September 2020 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
KTKazuhiro Taguchi
Kazuhiro Taguchi
TOTakashi Onoe
Takashi Onoe
TYTomoaki Yoshida
Tomoaki Yoshida
YYYoshinori Yamashita
Yoshinori Yamashita
YTYuka Tanaka
Yuka Tanaka
HOHideki Ohdan
Hideki Ohdan
Tumor endothelial cells (TEC) play multiple roles in the regional specialization of vascular structure and physiology. Because TECs in the tumor microenvironment come in contact with circulating immune cells, they might influence not only trafficking but also the antitumor cellular immune response. In a mouse tumor implantation model with B16 melanoma cells, TECs expressed MHC class II, costimulating molecules, and programmed death-ligand 1 (PD-L1), suggesting that they are antigen (Ag)-presenting cells with suppressive activity. Furthermore, TECs were able to take up and present tumor-derived ovalbumin (OVA) peptide on MHC class I molecules. In functional assays, B16-OVA tumor–derived TECs significantly suppressed the proliferation and Ag-specific cytotoxicity of OVA-specific CD8+ T cells relative to those of B16 tumor–derived TECs. This suppressive activity required cell–cell contact and was abrogated by PD-L1 blockade. TECs impaired proinflammatory cytokine production of CD8+ T cells, including IL2, TNFα, and IFNγ. B16-OVA tumor–derived TECs induced immunosuppressive CD4+ T cells that suppressed OVA-specific CD8+ T-cell proliferation via inhibitory cytokines, including IL10 and TGFβ. Deficiency of PD-L1 in TECs, but not in hematopoietic cells, impaired suppression and apoptosis of tumor-infiltrating CD8+ T cells, resulting in inhibition of tumor development in vivo model. These data suggest that TECs might regulate the immune response of tumor Ag–specific CD8+ T cells via the PD-1/PD-L1 pathway and induce immune suppressive CD4+ T cells in an Ag-specific manner, contributing to tumor immune evasion. Implications: The findings of this study might encourage the further development of novel anticancer therapies and strategies.

18 December 2019 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
TOTakashi Onoe
Takashi Onoe
MYMegumi Yamaguchi
Megumi Yamaguchi
TIToshimitsu Irei
Toshimitsu Irei
KIKohei Ishiyama
Kohei Ishiyama
TSTakeshi Sudo
Takeshi Sudo
HTHirotaka Tashiro
Hirotaka Tashiro

27 June 2013 in Transplantation
Verified
Journal Article
Closed access
TOTakashi Onoe
Takashi Onoe
YTYuka Tanaka
Yuka Tanaka
KIKentaro Ide
Kentaro Ide
KIKouhei Ishiyama
Kouhei Ishiyama
AOAkihiko Oshita
Akihiko Oshita
HOHideki Ohdan
Hideki Ohdan
Background Small-for-size syndrome remains the greatest limiting factor of expanding segmental liver transplantation from living donors. Portal hyperperfusion is considered to substantially contribute to small-for-size syndrome. We investigated the impact of continuous portal infusion of prostaglandin E1 (PGE1) on small-for-size grafts (SFSGs) in adult-to-adult living-donor liver transplantation (LDLT). Methods From July 2003 to December 2009, LDLT was performed in 122 patients. We introduced continuous portal infusion of PGE1 to five SFSG patients (PG group) from November 2007 to December 2009 and retrospectively compared them with a historical control group of eight relevant SFSG patients without PGE1 infusion (non-PG group) from July 2003 to October 2007 to determine the safety and efficacy of continuous PGE1 portal infusion for SFSGs. Splenectomy cases were excluded from analysis. Results The PG group demonstrated significantly lower postoperative portal pressure than the non-PG group. Moreover, the PG group demonstrated significantly improved liver function in the early posttransplantation period and significantly better recovery from hyperammonemia at 1 week after transplantation and from hyperbilirubinemia in the late posttransplantation period. Overall survival was significantly better in the PG group than in the non-PG group. Three patients in the non-PG group died of rejection-related reasons. Interestingly, immunomonitoring assay revealed that antidonor immune responses were significantly accelerated in the non-PG group compared with the PG group after LDLT. In contrast, the PG group showed well-suppressed antidonor immune responses. Conclusion Continuous portal infusion of PGE1 for SFSG attenuated portal hypertension, improved graft function, and suppressed antidonor immune responses, resulting in better survival.

1 April 2014 in Transplantation Proceedings
Verified
Journal Article
Closed access
TAT. Abe
T. Abe
TOT. Onoe
T. Onoe
HTH. Tahara
H. Tahara
HTH. Tashiro
H. Tashiro
KIK. Ishiyama
K. Ishiyama
HOH. Ohdan
H. Ohdan

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
TOTakashi Onoe
Takashi Onoe
HTHiroyuki Tahara
Hiroyuki Tahara
YTYuka Tanaka
Yuka Tanaka
HOHideki Ohdan
Hideki Ohdan
Liver transplantation (LT) is a considerably effective treatment for patients with end-stage hepatitis B virus (HBV)-related liver disease. However, HBV infection often recurs after LT without prophylaxis. Since the 1990s, the treatment for preventing HBV reinfection after LT has greatly progressed with the introduction of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NAs), resulting in improved patient survival. The combination therapy consisting of high-dose HBIG and lamivudine is highly efficacious for preventing the recurrence of HBV infection after LT and became the standard prophylaxis for HBV recurrence. However, mainly due to the high cost of HBIG treatment, an alternative protocol for reducing the dose and duration of HBIG has been evaluated. Currently, combination therapy using low-dose HBIG and NAs is considered as the most efficacious and cost-effective prophylaxis for post-LT HBV reinfection. Recently, NA monotherapy and withdrawal of HBIG from combination therapy, along with the development of new, potent high genetic barrier NAs, have provided promising efficacy, especially for low-risk recipients. This review summarizes the prophylactic protocol and their efficacy including prophylaxis of de novo HBV infection from anti-HBc antibody-positive donors. In addition, challenging approaches such as discontinuation of all prophylaxis and active immunity through hepatitis B vaccination are discussed.